Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials

Cell Cycle. 2007 Jun 1;6(11):1336-41. doi: 10.4161/cc.6.11.4359. Epub 2007 Jun 27.

Abstract

Single therapeutic agents very often fail in unselected patients. It is therefore commonplace to combine an agent specifically with a selected patient subgroup or with another agent. To support such efforts, it is useful to clarify the distinctions between the terms and the mathematical models used in analyzing combinations. To incorporate molecular disease classifications, the familiar concept of the therapeutic window is modified to define a pharmacogenetic window, which is an unambiguous numerical measure of the magnitude of interaction produced by a combination, and to define a test of pharmacogenetic synergy. In contrast, certain common comparative methods, such as vertical windows (comparing effects at a given dose) and animal models of mutational targets may be dominated by undesirable features. Although this discussion is oriented towards cancer therapy, an extension of these concepts to other comparative biologic assays is feasible and advisable.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
  • Biotransformation / genetics
  • Clinical Trials as Topic / methods*
  • Dose-Response Relationship, Drug
  • Drug Design
  • Drug Evaluation, Preclinical
  • Drug Interactions*
  • Drug Screening Assays, Antitumor
  • Drug Synergism
  • Drug Therapy, Combination*
  • Genetic Variation
  • Humans
  • Inhibitory Concentration 50
  • Models, Animal
  • Models, Biological
  • Neoplasms / drug therapy
  • Neoplasms / genetics
  • Patient Selection
  • Pharmacogenetics*
  • Research Design / standards*
  • Terminology as Topic

Substances

  • Antineoplastic Agents